The responses of 1,948 women aged 40 to 49 were detailed recently in Academic Radiology, where researchers offered detailed insight into what factors influence women at average risk of breast cancer to seek or delay screening at certain ages. 

This image gallery shows what the various clinical presentations associated with the COVID-19 virus that have been documented during the coronavirus pandemic.

The FDA’s Center for Devices and Radiological Health (CDRH) has updated the status of two previously disaccredited mammography operations, rehabilitating the reputation of one while showing the other in limbo.

Since 2006, the FDA has recommended MRI screenings as a way to detect asymptomatic breast implant ruptures—but many patients seem unaware of or are actively ignoring the guidance. 

Multiple areas of architectural distortion visualized on digital breast tomosynthesis (DBT) exams are likely to produce high-risk pathology results. 

The new guidelines put emphasis on the age at which average-risk women should begin annual screening and breast assessments.

Women who skipped screening due to financial concerns outnumbered those who were not screened due to logistical issues such as scheduling and transportation conflicts, new survey data reveals. 

Experts found that although abbreviated protocols increased the amount of possible scans per hour from 4.7 to 18.8, non-scanning time rose from 50% to 74%.